A Phase II, Open-Label Trial of Bortezomib (Velcade) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase II, Open-Label Trial of Bortezomib (Velcade) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Planned end date changed from 16 Apr 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 03 Jul 2012 New source identified and integrated (NCT01633645: ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top